A citation-based method for searching scientific literature

Yoshiko Nanki, Hiroyuki Nomura, Naomi Iwasa, Keiko Saotome, Ai Dozen, Tomoko Yoshihama, Takuro Hirano, Shiho Hashimoto, Tatsuyuki Chiyoda, Wataru Yamagami, Fumio Kataoka, Daisuke Aoki. Jpn J Clin Oncol 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Sandro Pignata, Domenica Lorusso, Florence Joly, Ciro Gallo, Nicoletta Colombo, Cristiana Sessa, Aristotelis Bamias, Vanda Salutari, Frédèric Selle, Simona Frezzini,[...]. Lancet Oncol 2021
11
100



Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias,[...]. J Clin Oncol 2014
766
100

Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.
A P M Heintz, F Odicino, P Maisonneuve, M A Quinn, J L Benedet, W T Creasman, H Y S Ngan, S Pecorelli, U Beller. Int J Gynaecol Obstet 2006
513
100

Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011
100

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Jaafar Bennouna, Javier Sastre, Dirk Arnold, Pia Österlund, Richard Greil, Eric Van Cutsem, Roger von Moos, Jose Maria Viéitez, Olivier Bouché, Christophe Borg,[...]. Lancet Oncol 2013
720
100

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
Robert A Burger, Michael W Sill, Bradley J Monk, Benjamin E Greer, Joel I Sorosky. J Clin Oncol 2007
569
100

Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.
Xavier Paoletti, Liz-Anne Lewsley, Gennaro Daniele, Adrian Cook, Nozomu Yanaihara, Anna Tinker, Gunnar Kristensen, Petronella B Ottevanger, Gerasimos Aravantinos, Austin Miller,[...]. JAMA Netw Open 2020
11
100

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.
Gavin C E Stuart, Henry Kitchener, Monica Bacon, Andreas duBois, Michael Friedlander, Jonathan Ledermann, Christian Marth, Tate Thigpen, Edward Trimble. Int J Gynecol Cancer 2011
273
100

Detecting an overall survival benefit that is derived from progression-free survival.
Kristine R Broglio, Donald A Berry. J Natl Cancer Inst 2009
340
100


Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
Masayuki Takeda, Takeharu Yamanaka, Takashi Seto, Hidetoshi Hayashi, Koichi Azuma, Morihito Okada, Shunichi Sugawara, Haruko Daga, Tomonori Hirashima, Kimio Yonesaka,[...]. Cancer 2016
31
100

Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer.
Mototsugu Shimokawa, Takahiro Kogawa, Takako Shimada, Toshiaki Saito, Hozumi Kumagai, Masafumi Ohki, Tsunehisa Kaku. J Cancer 2018
8
100

Tumor angiogenesis.
Robert S Kerbel. N Engl J Med 2008
100

Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
Amreen Husain, Yan Wang, Lars C Hanker, Belén Ojeda, Maarit Anttila, Enrico Breda, Peter Vuylsteke, Eric Pujade-Lauraine. Gynecol Oncol 2016
12
100

Continuous Administration of Bevacizumab After Disease Progression in Recurrent Ovarian Cancer: A Retrospective Observational Study.
Terumi Tanigawa, Maki Matoda, Makiko Omi, Yoichi Aoki, Sachiho Netsu, Hidetaka Nomura, Sanshiro Okamoto, Kohei Omatsu, Mayu Yunokawa, Hiroyuki Kanao,[...]. Anticancer Res 2020
1
100

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
781
100

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.
E Vrdoljak, N Marschner, C Zielinski, J Gligorov, J Cortes, F Puglisi, M Aapro, L Fallowfield, A Fontana, M Inbar,[...]. Ann Oncol 2016
20
100



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.